NeoGenomics: Warren Stone
NeoGenomics has promoted Chief Commercial Officer Warren Stone to president and chief operating officer (COO), effective April 1. Stone has over 25 years of general management and commercial experience. In his expanded role, he will be responsible for driving the company's lab operations, data solutions division, and enterprise operations functions. Before joining NeoGenomics in 2022, Stone was president of the Americas at Ortho Clinical Diagnostics and senior VP at MilliporeSigma. He earned his MBA from Suffolk University and has a B.A.Sc. in analytical chemistry from Technikon Witwatersrand South Africa. Current NeoGenomics COO Melody Harris will leave the firm at the end of May.
ACMG: Christa Martin, Josh Deignan, Lauren Massingham, David Miller, Douglas Stewart, William Wilcox
The American College of Medical Genetics and Genomics appointed six new directors, including a new president-elect, to its board at the 2025 ACMG Annual Clinical Genetics Meeting in Los Angeles this week.
The newly elected directors, who will serve six-year terms from March 2025 to March 2031 are:
- President-elect Christa Martin, currently CSO at Geisinger and vice dean for research at Geisinger's School of Medicine. Martin earned her Ph.D. in human genetics from the University of Pittsburgh and completed her postdoc at the University of Chicago, where she became board-certified in clinical cytogenetics. At Geisinger, she has pioneered initiatives like the MyCode Community Health Initiative and was the founding director of Geisinger's Autism & Developmental Medicine Institute.
- Josh Deignan, a board-certified clinical geneticist and clinical professor of pathology and laboratory medicine at the David Geffen School of Medicine at the University of California, Los Angeles.
- Lauren Massingham, a board-certified medical geneticist and current director of the cancer genetic program at Hasbro Children's Hospital and Rhode Island Hospital.
- David Miller, a board-certified clinical geneticist who directs the Neurofibromatosis Research Initiative at Boston Children's Hospital and is also an associate molecular pathologist at Brigham and Women's Hospital.
- Douglas Stewart, a board-certified medical geneticist and internist who serves as a senior investigator at the National Cancer Institute and adjunct investigator at NHGRI.
- William Wilcox, a board-certified clinical geneticist and biochemical geneticist who serves as medical director of the Emory Genetic Clinical Trials Center and is the founder of the Medical Biochemical Genetics Training Program at Emory.
Seek Labs: Kim Wirthlin
Point-of-care testing and therapeutics firm Seek Labs has appointed Kim Wirthlin as its chief strategy officer, effective March 17. She has more than 25 years of experience in university leadership, government relations, academic healthcare, and early-stage company development. Prior to joining Salt Lake City-based Seek Labs, Wirthlin was president and chief operating officer of the Huntsman Cancer Foundation. Before that she spent 18 years as a member of the executive management team at University of Utah Health.
For additional recent items on executive appointments, promotions, and departures in the omics and molecular diagnostics space, please see the People in the News page on our website.